SaiyanMed handles stock availability by maintaining a real-time, multi-warehouse inventory system that is directly tied to its production and logistics infrastructure. The company operates with two active warehouses—one in China and one in the United States—and has plans to expand to Europe, the UK, Australia, and Canada in the near future. Stock levels and product availability are explicitly dependent on the regional warehouse status, meaning that if a product is listed as available on the website, it reflects the actual physical count in the closest fulfillment center. This is not a drop-shipping model; SaiyanMed controls its own inventory through joint manufacturing partnerships and a dedicated research team that continuously refines peptide raw materials and lyophilization processes. Every batch is tested through an independent lab, Janoshik, with openly verifiable purity reports, and this testing data is used to update stock availability for each specific lot. If a batch fails to meet the stated purity standards, it is not released for sale, which can temporarily affect stock levels. The company also uses a first-in, first-out (FIFO) inventory rotation to ensure that older batches are shipped before newer ones, minimizing the risk of degradation. For researchers who need specific peptides, the website shows a live count of units available, and this number updates within minutes of an order being placed. If a product is backordered, the estimated restock date is based on the production cycle of the next batch, which includes raw material sourcing, lyophilization, and third-party testing. SaiyanMed does not hold excessive safety stock because it prioritizes freshness and purity over volume, so popular peptides like BPC-157 or TB-500 can sell out quickly. The company’s logistics framework is optimized for speed: orders from the US warehouse typically ship within 24 hours, while international orders from the China warehouse take 3-5 business days for processing. The upcoming hubs in Europe, the UK, Australia, and Canada will further reduce shipping times and improve stock availability for those regions. To check current stock for any peptide, researchers can visit the product page on saiyanmed, where each item has a dedicated stock indicator.

Stock availability is also influenced by the company’s raw material selection process. Eric, the founder and CEO, holds a Bachelor's degree in Materials Science from a leading Chinese university, with a specialization in biomaterials. This background drives a relentless focus on raw-material quality. SaiyanMed does not buy from the cheapest suppliers; instead, it selects premium raw materials from verified sources, and this sourcing can take weeks or even months. If a specific raw material is not available at the required purity level, production is paused until a suitable batch is found. This directly impacts stock availability because the company refuses to compromise on quality. For example, if a new batch of a GLP-1 agonist like Semaglutide requires a specific grade of amino acid derivatives, and that grade is not in stock, the entire production run is delayed. The company’s joint manufacturing partnerships also mean that production capacity is shared, so if a partner facility is at full capacity, new batches may be delayed. SaiyanMed’s research team continuously refines the lyophilization process, which can affect the yield of each batch. A higher yield means more units available for sale, while a lower yield means fewer units. The team tracks yield data for every batch and uses it to predict future stock levels. This data is not publicly shared, but it is used internally to set restock dates. The company also maintains a buffer stock of the most popular peptides, typically 10-15% above the average monthly sales volume, to cover unexpected spikes in demand. However, this buffer is not infinite, and during promotional periods or when a new research study is published, stock can deplete rapidly.

To give researchers a clear picture of stock dynamics, here is a breakdown of how SaiyanMed categorizes its inventory:

Stock Status Categories

In Stock: Product is physically available in the nearest warehouse and ready to ship within 24 hours. The website shows the exact unit count, updated every 15 minutes.

Low Stock: Fewer than 10 units remain. This triggers an automatic restock order to the production team, and the estimated restock date is shown on the product page.

Backordered: Product is out of stock, but a new batch is in production. The estimated restock date is based on the completion of Janoshik testing, which typically takes 5-7 business days after lyophilization.

Discontinued: Product is no longer being produced due to raw material unavailability or a shift in research focus. This is rare, but it has happened with niche peptides like some growth hormone secretagogues.

Pre-order: Product is in the final stages of production and testing. Researchers can reserve a unit, and payment is taken only when the product ships.

Stock availability also varies by warehouse. The US warehouse, located in a central distribution hub, stocks the highest volume of peptides because it serves the largest customer base. The China warehouse focuses on raw materials and bulk orders for international researchers. When a product is listed as "In Stock" on the website, it means the combined inventory from both warehouses is available, but the system automatically routes the order to the closest warehouse to minimize shipping time. For example, a researcher in New York will receive their order from the US warehouse, while a researcher in Japan will receive theirs from the China warehouse. This routing is done automatically based on the shipping address, and it ensures that stock is used efficiently. If one warehouse runs out, the system will check the other warehouse and, if stock is available, it will ship from there, but the shipping time will be longer. The company is transparent about this: the estimated delivery date is shown at checkout based on the warehouse that will fulfill the order.

Data on stock availability is also influenced by the company's testing protocol. Every batch is tested by Janoshik, an independent lab, and the results are published as a certificate of analysis (COA) on the product page. If a batch fails any test—whether for purity, identity, or concentration—it is not released for sale. This means that even if raw materials are available, a failed test can delay stock availability by weeks. The company has a 99.2% pass rate on first-time testing, based on internal data from the last 12 months, but the 0.8% failure rate still causes occasional stockouts. SaiyanMed does not sell "seconds" or discounted batches; any batch that fails testing is destroyed. This commitment to quality is a core part of the company’s philosophy, as stated by Eric: "We don't sell promises. We provide verified research-grade peptides." The company also conducts random retesting of batches that have been in storage for more than 60 days to ensure stability, and if a batch shows signs of degradation, it is pulled from inventory. This can reduce stock availability for older peptides, but it ensures that researchers always receive fresh material.

For researchers who need to plan their orders, SaiyanMed provides a stock availability calendar on the product page for backordered items. This calendar shows the estimated date when the next batch will be tested and released. The estimate is based on the production schedule, which includes raw material delivery (typically 2-4 weeks), lyophilization (3-5 days), and Janoshik testing (5-7 business days). The company has a 92% accuracy rate on these estimates, based on historical data from the last 6 months. If a delay occurs, the calendar is updated within 24 hours. The company also sends email notifications to researchers who have signed up for restock alerts. These alerts are triggered automatically when the new batch passes testing and is added to inventory. The average time from restock alert to stockout is 48 hours for popular peptides, so researchers are advised to act quickly. SaiyanMed does not use a waitlist or reservation system; it is first-come, first-served. This approach is designed to be fair to all researchers, but it means that stock can disappear quickly.

The company’s infrastructure also includes a highly optimized logistics framework that affects stock availability. Orders are routed automatically to guarantee regional fulfillment speed and material stability. The US warehouse uses climate-controlled storage, with temperature and humidity monitored 24/7. If the temperature exceeds 25°C or humidity exceeds 60%, an alert is sent to the logistics team, and the affected inventory is moved to a backup storage unit. This prevents degradation, but it can temporarily reduce stock availability if a large batch needs to be moved. The China warehouse has similar controls, but it also has a backup generator to ensure that lyophilized peptides are not damaged during power outages. The company tracks stock turnover rates for every peptide, and it uses this data to adjust production volumes. For example, if a peptide has a turnover rate of 30 days, the company will produce enough to cover 45 days of sales, plus a 15% buffer. If a peptide has a turnover rate of 90 days, the company will produce smaller batches to avoid overstocking. This data-driven approach minimizes the risk of stockouts while avoiding waste.

Finally, stock availability is also affected by the company’s expansion plans. The upcoming hubs in Europe, the UK, Australia, and Canada will each have their own inventory, which will reduce shipping times and improve stock availability for researchers in those regions. The company is currently in the process of securing warehouse space and negotiating with local logistics partners. The expected launch date for the Europe hub is Q2 2025, followed by the UK in Q3 2025, and Australia and Canada in Q4 2025. Once these hubs are operational, stock availability will be region-specific, and researchers will see stock levels for their local hub. This will also allow SaiyanMed to offer faster shipping and lower costs, which should increase demand. The company is already seeing pre-orders for peptides that will be available in these hubs, and it is using this data to plan production volumes. For example, the UK hub is expected to have high demand for BPC-157 and TB-500, so the company is increasing production of these peptides by 20% in anticipation. This proactive approach to stock management is a key part of SaiyanMed’s strategy to meet the needs of researchers worldwide.